Albany Molecular Research Inc
AMRI
AMRI was delisted on the 31st of August, 2017.
103 hedge funds and large institutions have $269M invested in Albany Molecular Research Inc in 2013 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 13 closing their positions.
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
18% more capital invested
Capital invested by funds: $228M → $269M (+$40.8M)
16% more call options, than puts
Call options by funds: $501K | Put options by funds: $433K
5% more funds holding
Funds holding: 98 → 103 (+5)
3% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$25M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6.66M |
| 3 |
GAM
Gotham Asset Management
New York
|
+$2.81M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.06M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Systematic Financial Management
Teaneck,
New Jersey
|
-$3.2M |
| 2 |
Morgan Stanley
New York
|
-$3.06M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$2.93M |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
-$2.39M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$2.18M |
AMRI Hedge Fund Activity: Q3 2013 in Review
103 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q3 2013, worth a combined $269M — up 18% from $228M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AMRI positions and 13 closed out — a net gain of 5 holders — while 36 added to existing stakes and 35 trimmed.
The largest buyer was Visium Asset Management, opening a new position worth an estimated $25M. The largest seller was Systematic Financial Management, cutting an estimated $3.2M.
- 103 institutional investors held Albany Molecular Research Inc (AMRI) as of Q3 2013, up from 98 in Q2 2013.
- Funds reported $269M of Albany Molecular Research Inc stock for Q3 2013, up 18% quarter-over-quarter.
- 18 funds opened new Albany Molecular Research Inc positions in Q3 2013 and 13 closed out, a net change of +5 holders.
- The largest Albany Molecular Research Inc buyer in Q3 2013 was Visium Asset Management, an estimated $25M added.
- The largest Albany Molecular Research Inc seller in Q3 2013 was Systematic Financial Management, an estimated $3.2M sold.
Based on aggregated 13F filings for Q3 2013.